The class of Rslcan-12 Inhibitors encompasses a diverse array of chemical compounds that, by targeting key components and nodes within cellular signaling and regulatory mechanisms, could indirectly influence the function or expression of the protein encoded by the gene Rslcan-12. This conceptual framework is predicated on the assumption that Rslcan-12 plays a role in cellular processes such as signal transduction, gene expression regulation, or protein turnover, which are regulated by intricate networks of signaling pathways.
These inhibitors demonstrate the complexity of cellular regulation and the potential for indirect modulation of protein function through strategic intervention in key signaling and regulatory pathways. For example, compounds that inhibit signal transduction molecules, such as LY294002 and U0126, target the PI3K/AKT and MAPK/ERK pathways, respectively, potentially impacting downstream effects that could modulate the activity or regulation of Rslcan-12. Similarly, inhibitors of protein degradation pathways, like Bortezomib, highlight the role of protein turnover in regulating the levels of specific proteins, including potentially Rslcan-12.
Furthermore, the action of these compounds underscores the interconnectedness of signaling pathways and the potential for a single chemical to influence multiple cellular processes. This reflects the multifaceted nature of cellular regulation and the potential for indirect modulation of gene function through the strategic targeting of related signaling mechanisms. Through their action, the chemicals classified as Rslcan-12 Inhibitors provide a means to explore and potentially influence the signaling networks and regulatory mechanisms that govern the function of proteins like Rslcan-12, offering insights into the complex regulatory networks that underpin cellular function and the role of specific genes within these networks. This approach to understanding the potential inhibitors of Rslcan-12 illustrates the broader implications of targeting signaling pathways for modulating protein activity and highlights the intricate web of interactions that govern cellular signaling and regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Inhibits calcineurin, potentially affecting NFAT signaling pathways that could be regulated by Rslcan-12. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, potentially impacting cell growth and proliferation pathways that Rslcan-12 may be involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially influencing stress response and inflammatory signaling pathways related to Rslcan-12 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, potentially affecting the PI3K/AKT signaling pathway, which could indirectly modulate Rslcan-12's role in cellular signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK1/2, potentially affecting the MAPK/ERK pathway, which Rslcan-12 may influence. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is part of the MAPK/ERK pathway, potentially altering signaling pathways regulated by Rslcan-12. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially modifying stress and apoptosis signaling pathways that could intersect with Rslcan-12-related processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, affecting a broad range of cellular processes including signaling pathways that Rslcan-12 may be part of. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor, can change chromatin structure and gene expression, possibly affecting Rslcan-12. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, could modulate signaling pathways potentially relevant to Rslcan-12's role in cellular signaling. | ||||||